Systematic Reviews
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Jun 28, 2018; 6(2): 9-20
Published online Jun 28, 2018. doi: 10.13105/wjma.v6.i2.9
Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors
Stephanie M Barrows, Beilei Cai, Catherine Copley-Merriman, Kelly R Wright, Colleen V Castro, Raoudha Soufi-Mahjoubi
Stephanie M Barrows, Catherine Copley-Merriman, Kelly R Wright, RTI Health Solutions, Ann Arbor, MI 48108, United States
Beilei Cai, Raoudha Soufi-Mahjoubi, Novartis Pharmaceuticals, East Hanover, NJ 07936, United States
Colleen V Castro, RTI Health Solutions, Research Triangle Park, NC 27709, United States
Author contributions: Barrows SM did the data curation, project administration and writing (original draft, review and editing); Cai B did the conceptualization, funding acquisition and supervision; Copley-Merriman C did the data curation, supervision and writing (review and editing); Wright KR and Castro CV contributed to the data curation and methodology; Soufi-Mahjoubi R did the conceptualization and supervision; all authors provided review and approval of the final version.
Conflict-of-interest statement: Beilei Cai and Raoudha Soufi-Mahjoubi are employees of Novartis Pharmaceuticals. RTI-HS received funding from Novartis Pharmaceuticals to conduct this work.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Stephanie M Barrows, MA, MPH, Research Scientist, Senior Director, RTI Health Solutions, 3005 Boardwalk St., Suite 105, Ann Arbor, MI 48108, United States. sbarrows@rti.org
Telephone: +1-734-2135419 Fax: +1-734-2136169
Received: March 23, 2018
Peer-review started: March 23, 2018
First decision: April 18, 2018
Revised: April 26, 2018
Accepted: May 15, 2018
Article in press: May 15, 2018
Published online: June 28, 2018
Processing time: 97 Days and 14.7 Hours
Core Tip

Core tip: This review comprehensively summarizes the existing clinical trial and observational studies that have assessed long-acting octreotide’s tumor control effect. The comparative studies of relatively large sample size support long-acting octreotide’s antitumor effect on time to tumor progression and overall survival. This review shows the rarity of existing studies assessing octreotide’s antitumor effect; future research is warranted.